polymyxin b derivatives

AureoGen Biosciences is developing a series of **polymyxin B derivatives** as next-generation cyclic peptide antibiotics. These compounds are engineered to address the limitations of traditional polymyxins, specifically targeting multi-drug resistant (MDR) Gram-negative bacterial infections such as *Pseudomonas aeruginosa* and *Acinetobacter baumannii*, as well as Gram-positive pathogens like methicillin-resistant *Staphylococcus aureus* (MRSA). The mechanism of action typically involves binding to the lipopolysaccharide (LPS) of the bacterial outer membrane in Gram-negative species, leading to membrane disruption, increased permeability, and bactericidal activity. AureoGen's development program focuses on utilizing a chemistry-driven approach to modify natural product leads, aiming to enhance therapeutic efficacy while significantly reducing the nephrotoxicity and neurotoxicity commonly associated with clinical use of polymyxin B and colistin.

Other names

Polymyxin B derivatives